month MB Multi-drug Therapy (MDT). He had no complaints of such attacks during treatment. He also complained of multiple joint pains along with pain along the medial border of left hand. On examination, the patient had multiple subcutaneous nodules of which a few had ulcerated over the back, face, and forearms. No skin patch was visible but there was diffuse skin infiltration with some areas of sparing. Both the ulnar nerves were thickened and the right ulnar had developed an abscess. Patient also had bilateral weakness of hands assessed by motor testing. The peripheral sensations were relatively preserved. On investigating, he had neutrophilia with toxic granules, slit skin smear was positive with a Bacillary Index (BI) of 3.75+ and Morphological Index of -0. Liver function tests and renal function tests were all within normal limits. ELISA for HIV was negative. Chest X-Ray was normal. ) reported that almost half of the lepromatous cases and one quarter of borderline lepromatous cases experience ENL reaction. By definition, ENL is recurrent and self-limiting in the majority of cases. But some patients behave differently and are resistant to all modalities. Depending upon the severity of the ENL, various drugs are used ranging from non-steroidal anti-inflammatory agents in mild cases to corticosteroids and thalidomide ( 2 ) in severe cases. Thalidomide acts as a wonder drug in severe ENL ( 3 ) but it has its own limitations. Non-availability and high cost are the two major issues concerned with the routine use of the drug. The drug has to be given under supervision and is contraindicated in women of childbearing age in most of the countries. So practically speaking, corticosteroids are the main stay in management of the condition. The WHO recommended dose is 40 mg/day ( 4 ) and majority respond to this regime. Prednisolone ( 2 ) acts by suppression of cell mediated immunity, inhibition of release of lysosomal enzymes and cytokines, decrease of fluid leakage at the site of inflammation, decrease in the response of neutrophils to chemotaxis, and inhibition of prostaglandin synthesis, etc. The drug has to be tapered over 4 months, though in some patients the dose has to be individualized. This is likely to lead to a lot of complications ( 5 ). So the use of this drug should be judicious and the search is always on to find an ideal steroid-sparing agent. Methotrexate is being used for the treatment of psoriasis since late 1950s ( 6 ) and remains one of the most commonly used antimetabolites in dermatology practice. Dermatologists have been using this drug routinely since then and the safety record is so far impressive though hepatic and bone marrow side effects are the major concerns ( 7 ). Low doses of methotrexate suppress division of mononuclear cells and inhibit their response to interleukin 2, suppress neutrophil and monocyte chemotaxis in vitro and in vivo, and depress Langerhans cell activity and leukotriene B4 synthesis by neutrophils ( 8, 9, 10, 11, 12, 13, 14 ) , which also contribute to the manifestations of ENL. So a synergistic action of methotrexate to corticosteroids is expected in ENL cases; in other words, it would act like a steroidsparing agent in those who are likely to be put on a high dose of prednisolone for a prolonged period. Taking into consideration the side ef fects of methotrexate, the risk benefit ratio should be carefully calculated and individualized while combining it with prednisolone for the steroid resistant cases. Double blind controlled trials are welcome in the near future.
